Skip to main content
. 2013 Mar 3;2013:689236. doi: 10.1155/2013/689236

Table 3.

Secondary outcomes.

Outcome Baseline Mean difference ± SE (95% CI) P value 2 years Mean difference
± SE (95% CI)
P value Time by treatment interaction (F; significance)
SF-36 PCS
 Active 51.9 ± 19.2 11.8 ± 7.0 67.6 ± 16.3 30.5 ± 5.6
 Control 39.7 ± 17.8 (−2.2, 25.8) 0.1 37.1 ± 14.9 (18.5, 42.6) <0.001* F = 5.8; P = 0.02
SF-36 MCS
 Active 64.7 ± 19.6 14.1 ± 7.2 73.7 ± 13.1 16.9 ± 4.8
 Control 50.3 ± 19.7 (−0.5, 28.6) 0.1 56.8 ± 12.5 (7.2, 26.6) <0.001* F = 0.032; P = 0.86
Knee Society Knee Score
 Active 58.1 ± 18.8 3.4 ± 6.8 77.8 ± 12.1 17.8 ± 4.7
 Control 54.1 ± 16.3 (−10.3, 17.2) 0.6 60.0 ± 14.9 (8.3, 27.3) <0.001* F = 4.3; P = 0.044
Knee Society Function Score
 Active 57.1 ± 16.0 8.5 ± 6.5 74.6 ± 18.3 25.2 ± 6.9
 Control 47.2 ± 16.4 (−4.6, 21.7) 0.2 49.4 ± 19.3 (11.2, 39.0) <0.001* F = 6.5; P = 0.014

SF-36: Short Form 36 (SF-36).

*P ≤ 0.05 was considered statistically significant. Groups showed no significant differences at the baseline. Groups showed significant differences in all outcomes after two years. There was a significant difference in improvement over time between groups in all outcomes except for the SF-36 mental component summary (MCS).